PUBLIC COMPANY
save$RAREUltragenyx Pharmaceutical Inc.
$RARE17.58+5.27%Novato, CA, USupdated 8h ago
Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases.
community read0 votes
pipeline
9
marketed
3
phase 3
4
catalysts ytd
5
approvals ytd
0
recalls ytd
0
Pipeline(9)
pipeline depth9 products
4Phase 33Marketed2pre_registration
Marketed
burosumab
X-Linked Hypophosphatemic Rickets
Marketedtriheptanoin
Fatty Acid Biosynthesis Disorders
Marketedvestronidase alfa
Mucopolysaccharidosis VII (MPS VII) (Sly Syndrome )
Phase 3apazunersen sodium
Angelman Syndrome
Phase 3avalotcagene ontaparvovec
Ornithine-Transcarbamylase Deficiency
Phase 3rivunatpagene miziparvovec
Wilson Disease
Phase 3setrusumab
Osteogenesis Imperfecta
Sclerostin
pre_registrationpariglasgene brecaparvovec
Glycogen Storage Disease 1A
pre_registrationrebisufligene etisparvovec
Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome )
Upcoming
Jan 15, 2027
pdufa
$RARE17.58+5.27%
Rare Disease PDUFA 2027-01-15
Rare Disease
→
Jan 21, 2027
pdufa
$RARE17.58+5.27%
Ultragenyx Pharmaceutical Inc. PDUFA 2027-01-21
Ultragenyx Pharmaceutical Inc.
→
Jan 21, 2027
pdufa
$RARE17.58+5.27%
Ultragenyx Pharmaceutical Inc. PDUFA 2027-01-21
Ultragenyx Pharmaceutical Inc.
→
Feb 1, 2027
pdufa
$RARE17.58+5.27%
mitapivat sulfate PDUFA 2027-02-01
mitapivat sulfate
→
Recent(90d)
earnings (1)
Active trials
- —Tumor-induced Osteomalacia Disease Monitoring Program
- phase2A Safety and Efficacy Study of GTX-102 in Subjects With Deletion- or Nondeletion-type Angelman Syndrome (AS)
- phase3Setrusumab vs Placebo for Osteogenesis Imperfecta
- phase3Setrusumab vs Bisphosphonates in Pediatric Subjects With Osteogenesis Imperfecta
- —Glycogen Storage Disease Type Ia (GSDIa) Disease Monitoring Program
- phase3A Study to Determine the Effect of Triheptanoin Compared With Even-Chain MCT on MCEs in Pediatric Patients With LC-FAOD
- phase3Phase I/II/III Gene Transfer Clinical Trial of scAAV9.U1a.hSGSH
- phase3Phase 3 Efficacy and Safety Study of GTX-102 in Pediatric Subjects With Angelman Syndrome (AS)
🐶 Hiring Signal
Where Ultragenyx Pharmaceutical Inc. is staffing up — a leading indicator of pipeline and commercial priorities.
therapeutic areaRare Disease 13
News
- FDA Approves First Drug to Treat Neurological Symptoms of Type 3 Gaucher DiseaseFDA today approved Infilbray (venglustat) tablets, the first treatment for the neurological symptoms of Type 3 Gaucher disease (GD3) in adults and pediatric patients weighing at least 15 kg (approx…fda_press · 10h ago
- White House pulls nomination for FDA nominee OvertonThe sudden end of Heidi Overton’s candidacy likely ensures a Democrat-controlled Congress will choose the FDA’s next leader — but shouldn’t disrupt the agency, analysts say.biopharma_dive · 12h ago
- CTAD 2026: Biogen, AriBio lead the way in slowing cognitive decline in Alzheimer’sBiogen and AriBio reported wins for their respective therapies targeting Alzheimer’s disease, while Priavoid and Cognito Therapeutics missed the mark—though the latter plans to file for FDA approva…biospace · 13h ago
- Merck scraps centerpiece of $2.7B ArQule buy after late-stage safety concernsMerck is canning multiple Phase 3 studies of nemtabrutinib after a benefit-risk review derailed hopes of the asset entering the non-covalent BTK inhibitor race.biospace · 14h ago
- Summit’s rejection, Isomorphic’s record $5B raise, obesity and Alzheimer’s in the spotlightThe FDA declined to approve Summit Therapeutics’ Akeso-partnered ivonescimab, putting other PD-1/VEGF drug developers on notice; Isomorphic bagged a $5 billion series C, the largest in biotech hist…biospace · 18h ago
- 5 acquisitions that forced Big Pharmas to co-parentAcquiring a biotech with an existing Big Pharma partner can impose financial and strategic constraints around data sharing and milestone and royalty payments—but it is “rarely a deal-breaker,” acco…biospace · 23h ago
- White House yanks Overton nomination hours before committee voteThe Trump administration withdrew the nomination of Heidi Overton for FDA commissioner Tuesday evening, reportedly due to opposition from Republican Senators.biospace · 1d ago
- Larbi Inc. Recalls Yellow Dock Root Because of Possible Health RiskLarbi Inc. of Valley Cottage, NY, is recalling three lots of Herb To Body Yellow Dock Root C/S 4oz, because it has the potential to be contaminated with Salmonella, an organism which can cause seri…fda_recalls · 1d ago
- Beren wins FDA approval for long-studied rare disease drugA molecule designed by government scientists more than a decade ago has won FDA approval to treat infantile-onset Niemann-Pick disease type C, capping a winding and rocky development path. Beren Th…endpoints · 1d ago
- FDA Approves First Drug Shown to Help Patients with Infantile-Onset Niemann-Pick Disease Type C Live LongerFDA approved Lembaz (adrabetadex) injection, the first treatment shown to help people with a severe form of Niemann-Pick disease type C (NPC) live longer.fda_press · 1d ago
Data sources
last refreshed 7m ago
Found something off?
comments(0)
5-min edit window · permanent after that